NeoGenomics, Inc. (NEO)

Market Cap	1.97B
Revenue (ttm)	644.12M
Net Income (ttm)	-77.73M
Shares Out	128.36M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	97.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,677
Open	15.29
Previous Close	15.36
Day's Range	15.04 - 15.49
52-Week Range	12.77 - 21.22
Beta	1.18
Analysts	Strong Buy
Price Target	20.25 (+31.84%)
Earnings Date	Nov 5, 2024

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detect...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1999
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO
• Website: https://www.neogenomics.com

Financial Performance

In 2023, NeoGenomics's revenue was $591.64 million, an increase of 16.07% compared to the previous year's $509.73 million. Losses were -$87.97 million, -39.02% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for NEO stock is "Strong Buy." The 12-month stock price forecast is $20.25, which is an increase of 31.84% from the latest price.

Price Target

$20.25

(31.84% upside)

Analyst Consensus: Strong Buy